肺癌免疫治疗进展  

Progress in immunotherapy for lung cancer

作　　者：郭佳[1] 陈志营[1] 谭平[1] 

机构地区：[1]吉林大学中日联谊医院呼吸内科,长春130033

出　　处：《国际呼吸杂志》2018年第4期290-296,共7页International Journal of Respiration

基　　金：吉林省级经济结构战略调整引导资金专项项目（高技术产业部分）（2015Y031-4）

摘　　要：肺癌是发病率、病死率最高的恶性肿瘤之一。除手术、化疗、放疗及分子靶向治疗外，免疫治疗的发展为肺癌治疗提供了新的手段。近年来，肿瘤疫苗、免疫检查点抑制剂等免疫治疗方法在基础研究及临床试验中均取得了一定进展。本文从经典免疫治疗及免疫靶向治疗2个方面综述肺癌免疫治疗进展。Lung cancer is one of the most common malignant tumors with high morbidity and mortality. In addition to surgery, chemotherapy, radiotherapy and molecular targeted therapy, the development of immunotherapy provides a new means for the treatment of lung cancer. Tumor vaccines, immune checkpoint inhibitors and other immunotherapy methods have made some progress in basic researches and clinical trials. This article reviews the advances in immunotherapy of lung cancer from two aspects：classical immunotherapy and targeted immunotherapy.

关 键 词：肺癌 免疫治疗 肿瘤疫苗 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]